REG - Shield Therapeutics - Grant of share options to the CEO

Shield TherapeuticsAnnouncement

06/06/2023 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230606:nRSF8095Ba&default-theme=true

RNS Number : 8095B  Shield Therapeutics PLC  06 June 2023

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Grant of share options to the Chief Executive Officer

 

London, UK, 06 June 2023: Shield Therapeutics plc (LSE: STX), a commercial
stage, pharmaceutical company with a focus on addressing iron deficiency with
its lead product Accrufer®/ Feraccru® (ferric maltol), announces that on 02
June 2023 it granted share awards in the form of options over ordinary shares
in the capital of the Company ("Ordinary Shares") under Shield Therapeutics'
Retention and Performance Share Plan ("RPSP").

 

In accordance with the requirements of the EU Market Abuse Regulations the
following options have been granted to Greg Madison who is deemed a PDMR:

 

 Name          Option Plan  Number of Ordinary Shares under Option  Vesting Date
 Greg Madison  RPSP         3,507,548                               Vesting occurs annually in three equal tranches and is not subject to
                                                                    performance conditions but is subject to Mr Madison remaining in office as at
                                                                    the date of vesting.
 Greg Madison  RPSP         3,507,548                               Vesting occurs on 02 June 2024 and is not subject to performance conditions
                                                                    but is subject to Mr Madison remaining in office as at the date of vesting.

 

Mr Madison currently holds 1,893,039 ordinary shares in the Company.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Greg Madison
 2.  Reason for the notification
 a)  Position/status                          Chief Executive Officer

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Shield Therapeutics plc
 b)  LEI code                                 213800G74QWY15FC3W71
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Options over new Ordinary Shares

     Identification code

                                              ISIN: GB00BYV81293
 b)  Nature of the transaction                Grant of awards over new Ordinary Shares under the Company's Retention and
                                              Performance Share Plan.
 c)  Price(s) and volumes(s)                  2023 RPSP Award

Price (£)   Volume
                                              6.8p        7,015,096

 
 d)  Aggregated information

     -  Aggregate volume                      Awards granted over 7,015,096 shares in total

     -  Price                                 6.8p exercise price

 e)  Date of the transaction                  02 June 2023
 f)  Place of the transaction                 Outside of trading venue

 

d)

Aggregated information

-  Aggregate volume

 

-  Price

 

 

Awards granted over 7,015,096 shares in total

 

6.8p exercise price

 

 

e)

Date of the transaction

02 June 2023

f)

Place of the transaction

Outside of trading venue

 

 

For further information please contact:

 

 Shield Therapeutics plc                                                                         www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Greg Madison, CEO                                                                               +44 (0) 191 511 8500
 Hans-Peter Rudolf, CFO

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel/Oliver Duckworth                                                                    +44 (0)20 7418 8900

 Joint Broker

 finnCap Ltd

 Geoff Nash/ George Dollemore/Alice Lane/Nigel                                                   +44 (0)20 7220 0500
 Birks

 Financial PR & IR Advisor
 Walbrook PR
 Lianne Applegarth/Alice Woodings                                                                +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 Investor Contact (US Advisor)

 LifeSci Advisors, LLC

 John Mullaly                                                                                    +1 617 429 3548 or jmullaly@lifesciadvisors.com

 

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral
therapy for adults with iron deficiency, with or without anemia.
Accrufer®/Feraccru® has a novel mechanism of action compared to other oral
iron therapies and has been shown to be an efficacious and well-tolerated
therapy in a range of clinical trials. More information about
Accrufer®/Feraccru®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com)

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on
addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric
maltol). The Group has launched Accrufer® in the US and Feraccru® is
commercialized in the UK and European Union by Norgine B.V., who also have the
marketing rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialization of Accrufer® / Feraccru® in China, Hong
Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea,
and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSSDSUMEDSESM